U.S. Energy Services Stock News

SWK Holdings (SWKH) closed out FY 2025 with fourth quarter revenue of US$6.6 million and a basic EPS loss of US$1.60, compared with revenue of US$9.2 million and basic EPS of US$0.48 in the same quarter a year earlier. The trailing twelve month EPS came in at a loss of US$0.21 on revenue of US$37.6 million. Over recent quarters, revenue has moved from US$9.2 million in Q4 2024 to US$12.2 million in Q1 2025, US$8.1 million in Q2 2025 and US$10.6 million in Q3 2025. Basic EPS shifted from...

Wondering whether GeneDx Holdings at around US$69.84 is a bargain or already pricing in a lot of optimism? This article walks through what the numbers currently say about value. The stock has had a choppy run, with a 10.2% decline over the last 7 days, a 14.9% decline over the last 30 days, a 47.2% decline year to date, a very large 3 year return, and a 33.1% decline over the last year. These swings have kept GeneDx on the radar for investors watching for changing expectations and risk...

Opera (NasdaqGS:OPRA) and Celo have agreed a restructured, multi year partnership that makes Opera a major network stakeholder in the Celo ecosystem. The deal centers on MiniPay and a planned push to drive global stablecoin usage across up to 50 million Opera users. The partnership includes a 160 million CELO allocation, expansion of MiniPay into new markets, and grassroots roadshows to support user adoption. Opera, trading at $14.36, now ties a bigger part of its fintech plans to the Celo...

Wondering if Hess Midstream at around US$39.59 is still offering value, or if most of the easy gains are already on the table. The stock has returned 1.5% over the last 7 days, 4.5% over the last 30 days, 14.3% year to date and 0.4% over the past year, with very large returns over the past 3 and 5 years of 85.1% and 173.4% respectively. Recent coverage has focused on Hess Midstream's role as a midstream infrastructure provider and how that positions the company within the broader energy...

Wondering if Innospec, at around its recent US$65.89 close, is offering value or a value trap? This review breaks down what the current share price really reflects. The stock has recently seen a 4% decline over the past week, an 18.9% decline over the past month, and a 29.9% decline over the last year, which may signal that the market is reassessing both growth potential and risk. Recent coverage of Innospec has focused on its position within the chemicals sector and how investors are...

TransUnion (NYSE:TRU) has rolled out new machine learning capabilities within its Device Risk fraud prevention solution. The update targets recent surges in digital fraud and suspected account takeovers, aiming to improve detection accuracy and reduce manual review work for clients. The company is highlighting adaptive, consortium driven risk scoring as a way to respond to more complex fraud patterns in digital channels. TransUnion enters this product update phase with its shares at $70.55...

In March 2026, AEye, Inc. announced it had joined the ANAB-accredited NVIDIA Halos AI Systems Inspection Lab to collaborate on validating safety, cybersecurity, and system integration of its Apollo, STRATOS, and OPTIS lidar solutions with NVIDIA DRIVE platforms. On the same day, AEye reported fourth-quarter 2025 sales of US$97,000 and a net loss of US$7.34 million, with full-year 2025 sales of US$233,000 and a net loss of US$33.96 million, showing modest revenue progress alongside continued...

TG Therapeutics, ticker NasdaqCM:TGTX, announced a new five year, $750 million senior secured credit facility with Blue Owl Capital. The agreement is described as non dilutive, meaning it does not involve issuing new equity to raise capital. The facility includes repayment of prior debt and could expand to as much as $1b in total available financing. TG Therapeutics focuses on developing and commercializing therapies in the biopharmaceutical space, where access to sizeable, flexible capital...

Investors may be wondering whether Progress Software's current share price reflects its true value, or if the recent weakness is opening up an opportunity. The stock closed at US$31.29, with returns of an 8.8% decline over 7 days, a 22.4% decline over 30 days, a 23.8% decline year to date, and a 42.5% decline over 1 year. These moves may have shifted how the market views its risk and reward trade off. Recent headlines have focused on Progress Software's role as a software provider and how...

If you are wondering whether RPC at US$6.83 is priced attractively or not, the starting point is understanding what the current market price might be implying about its future. Over the short term, the stock has returned 4.8% in the last 7 days, 12.0% over 30 days, 23.5% year to date, 28.6% over 1 year, and 38.1% over 5 years, while the 3 year return sits at a 4.0% decline. Recent coverage around RPC has focused on how investors are reassessing energy service providers, with attention on...

Jack Henry & Associates (NasdaqGS:JKHY) received the “Small Business Payments Solution of the Year” award at the FinTech Breakthrough Awards for its Tap2Local product. The recognition focuses on Tap2Local, a cloud-native payments solution designed for small business clients of banks and credit unions. For investors watching NasdaqGS:JKHY, this award offers insight into how the company is positioning itself within digital payments for community and regional financial institutions. Tap2Local...

To understand whether Waystar Holding at US$24.07 offers value or just looks cheap on the surface, you need to weigh the recent share performance against the fundamentals. Over the last week the stock returned 0.4% lower, over the last month it is 6.7% lower, and over the year it is 23.3% lower year to date and 35.8% lower over 1 year, which may signal that expectations and risk perceptions have shifted. Recent coverage has focused on Waystar Holding's position in healthcare services and...

In recent analyses, S&T Bancorp’s net interest income was found to have grown more slowly than the broader banking industry over the past five years and is now expected by sell-side analysts to decline by 5.3% in the coming 12 months, while earnings per share have fallen by 3.3% annually over the last two years on flat revenue. This combination of slowing core lending income and shrinking earnings, despite stable top-line performance, highlights ongoing pressure on the bank’s profitability...

Wondering if Alliant Energy’s current share price reflects its real worth, or if you might be paying too much for a regulated utility stock right now? The stock last closed at US$68.71, with a 7 day return of a 5.6% decline, a 30 day return of a 1.2% decline, a 1 year return of 12.5%, a 3 year return of 46.9%, and a 5 year return of 49.7%. These moves have come as investors continue to reassess regulated utilities as an income and stability option. Alliant Energy has attracted attention as...

Aveanna Healthcare Holdings (NasdaqGS:AVAH) announced the acquisition of Family First Homecare. The deal is intended to strengthen Aveanna's position in Florida and widen its geographic reach. The company also outlined a transformation that increased preferred payer agreements and set new M&A priorities for 2026. Aveanna Healthcare focuses on home based care services, an area many investors watch as care delivery shifts closer to the home. By adding Family First Homecare, the company is...

If you are wondering whether Enerpac Tool Group at around US$35.97 is a bargain, fairly priced, or looking stretched, this article walks through the key valuation angles to help you frame that question clearly. The stock is roughly flat over the last week with a 0.3% return. That sits against a 14.7% decline over the last month and a 14.8% decline over the last year, even as the 3 year and 5 year returns are 37.7% and 38.0% respectively. Recent coverage has focused on how Enerpac Tool Group...

Wondering if First Mid Bancshares at around US$39.44 is giving you fair value or a potential bargain? This article breaks down what the current price might be implying about the business. The stock is roughly flat over the last week at 0.1%, has seen a 9.2% decline over the past month, yet is still up 2.1% year to date and 15.5% over the last year, with a 59.7% return across three years and 0.4% over five years. Recent coverage around regional banks has focused on how share prices react to...

Wondering if Rezolve AI at US$2.53 is still priced for a turnaround or already baking in the story? This breakdown will help you frame what the current market price may be implying. The stock has been volatile recently, with a 5.9% decline over the last week, a 13.5% gain over the last month, an 11.8% year to date drop, and a 53.3% return over the past year, all set against a 74.9% decline over three years. Recent coverage has focused on Rezolve AI as an emerging player in the listed AI...

Starwood Real Estate Income Trust (OTCPK:SWDR) has posted its FY 2025 numbers with fourth quarter revenue of US$402.8 million, a basic EPS loss of US$0.39, and funds from operations of US$4.4 million in the red, setting the tone for a year where trailing twelve month revenue reached about US$1.6 billion alongside a net loss of US$691.6 million. Over recent quarters, revenue has moved in a tight band between US$389.7 million and US$420.2 million while EPS has remained in loss territory. As a...

In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal cancer screening test through its pharmacies, aiming to close care gaps with pharmacist-led services integrated into store workflows. At the same time, Exact Sciences highlighted new data on its Oncodetect molecular residual disease test and Cancerguard multi-cancer early detection assay at the...

Taysha Gene Therapies (NasdaqGS:TSHA) received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome. The company reported a 100% patient response rate in pivotal Phase I/II data for TSHA-102. Regulators aligned with Taysha on pivotal trial designs for its lead Rett syndrome program. Taysha added a key commercial hire as it prepares for potential TSHA-102 commercialization. Taysha Gene Therapies, trading at $4.4 per share, has been drawing attention as its 1 year return stands...

Ambarella (NasdaqGS:AMBA) used a recent industry conference to outline a faster push into Edge AI products. The company highlighted a major shift in its revenue mix, new sales efforts aimed at smaller customers, and progress on a semi custom chip. Management also disclosed work on an upcoming two nanometer chip, signaling a move to more advanced manufacturing nodes. Ambarella, trading at about $54.02, has seen a mixed share price record, with a 3.3% gain over the past week but a 28.1%...

Yiren Digital (YRD) is back in focus after Q4 2025 results showed revenue of CN¥957.63 million, a net loss of CN¥882.16 million, and a temporary suspension of its cash dividend for the second half of 2025. See our latest analysis for Yiren Digital. The earnings miss and dividend suspension appear to have weighed heavily on sentiment, with a 7 day share price return of 44.19% and a 1 year total shareholder return of 69.72%. The 3 year total shareholder return remains slightly positive, which...

HeartFlow (NasdaqGS:HTFL) reported landmark real world data at ACC 2026 showing its AI Plaque Analysis as a leading independent predictor for cardiovascular risk stratification. The Plaque Analysis data is linked with improved patient outcomes and substantial cost savings in coronary artery disease management. The company launched the large scale NAVIGATE PCI Registry to study its AI driven PCI Navigator tool ahead of commercial release. HeartFlow’s AI platform is now backed by FDA cleared...